{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:49:00Z","timestamp":1772754540600,"version":"3.50.1"},"reference-count":31,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.3892\/mmr.2012.1216","type":"journal-article","created":{"date-parts":[[2012,12,3]],"date-time":"2012-12-03T18:25:28Z","timestamp":1354559128000},"page":"425-430","source":"Crossref","is-referenced-by-count":16,"title":["Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells"],"prefix":"10.3892","volume":"7","author":[{"given":"LI","family":"JIANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RUO-YU","family":"LUO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JING","family":"YANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YAN-XIANG","family":"CHENG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2012,12,3]]},"reference":[{"key":"key20180108011816_b1-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1517\/14656566.2.1.109","article-title":"Current treatment for ovarian cancer","volume":"2","author":"Eltabbakh","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"key20180108011816_b2-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1517\/13543784.14.8.1033","article-title":"New-generation platinum drugs in the treatment of cisplatin-resistant cancers","volume":"14","author":"McKeage","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"key20180108011816_b3-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1517\/14728214.10.2.413","article-title":"Emerging drugs for ovarian cancer","volume":"10","author":"Tewari","year":"2005","journal-title":"Expert Opin Emerg Drugs"},{"key":"key20180108011816_b4-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fgene.2011.00067","article-title":"Epigenomics of ovarian cancer and its chemoprevention","volume":"2","author":"Chen","year":"2011","journal-title":"Front Genet"},{"key":"key20180108011816_b5-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2004.11.051","article-title":"Activation of PI3K\/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line","volume":"97","author":"Lee","year":"2005","journal-title":"Gynecol Oncol"},{"key":"key20180108011816_b6-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.bjc.6602332","article-title":"Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters","volume":"92","author":"Ferrandina","year":"2005","journal-title":"Br J Cancer"},{"key":"key20180108011816_b7-mmr-07-02-0425","first-page":"121","article-title":"Survivin expression in ovarian cancer","volume":"29","author":"Liguang","year":"2007","journal-title":"Exp Oncol"},{"key":"key20180108011816_b8-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000316049","article-title":"Quantitative detection of serum survivin and its relationship with prognostic factors in ovarian cancer","volume":"71","author":"No","year":"2011","journal-title":"Gynecol Obstet Invest"},{"key":"key20180108011816_b9-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/PAI.0b013e3181e30dcd","article-title":"Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma","volume":"19","author":"Qian","year":"2011","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"key20180108011816_b10-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.22426","article-title":"Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma","volume":"109","author":"Kleinberg","year":"2007","journal-title":"Cancer"},{"key":"key20180108011816_b11-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00018-002-8518-3","article-title":"Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer","volume":"59","author":"Zaffaroni","year":"2002","journal-title":"Cell Mol Life Sci"},{"key":"key20180108011816_b12-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1757-2215-4-20","article-title":"Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients","volume":"4","author":"Felisiak-Golabek","year":"2011","journal-title":"J Ovarian Res"},{"key":"key20180108011816_b13-mmr-07-02-0425","first-page":"275","article-title":"Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides","volume":"14","author":"Ma","year":"2005","journal-title":"Oncol Rep"},{"key":"key20180108011816_b14-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1158\/1535-7163.MCT-05-0423","article-title":"Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy","volume":"5","author":"Caldas","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"key20180108011816_b15-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1358\/mf.2006.28.9.1003581","article-title":"Effects of chemotherapy and\/or radiotherapy on survivin expression in ovarian cancer","volume":"28","author":"Zhang","year":"2006","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"key20180108011816_b16-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejogrb.2010.10.017","article-title":"Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors","volume":"155","author":"Zhang","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"key20180108011816_b17-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1677\/ERC-09-0308","article-title":"FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5","volume":"18","author":"Huang","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"key20180108011816_b18-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s11033-010-0365-y","article-title":"Protection of CHO cells by transfer of survivin driven by ovarian-specific promoter OSP-2","volume":"38","author":"Tu","year":"2011","journal-title":"Mol Biol Rep"},{"key":"key20180108011816_b19-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/jcb.24025","article-title":"IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation","volume":"113","author":"Roca","year":"2012","journal-title":"J Cell Biochem"},{"key":"key20180108011816_b20-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00432-012-1196-0","article-title":"Effect of shRNA targeting survivin on ovarian cancer","volume":"138","author":"Xing","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20180108011816_b21-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1349-7006.2010.01834.x","article-title":"Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models","volume":"102","author":"Nakahara","year":"2011","journal-title":"Cancer Sci"},{"key":"key20180108011816_b22-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1097\/00029330-200609020-00012","article-title":"Apoptosis of drug-resistant human ovarian carcinoma cell line COC1\/DDP induced by survivin antisense oligonucleotides","volume":"119","author":"Zheng","year":"2006","journal-title":"Chin Med J (Engl)"},{"key":"key20180108011816_b23-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejogrb.2009.04.035","article-title":"Aberration of the PI3K\/AKT\/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy","volume":"146","author":"Zhang","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"key20180108011816_b24-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.canlet.2008.08.027","article-title":"Implication of the Akt2\/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells","volume":"273","author":"Weng","year":"2009","journal-title":"Cancer Lett"},{"key":"key20180108011816_b25-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.canlet.2007.11.022","article-title":"Activation of fibronectin\/PI-3K\/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells","volume":"261","author":"Xing","year":"2008","journal-title":"Cancer Lett"},{"key":"key20180108011816_b26-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ygyno.2008.05.001","article-title":"Synergistic action of dietary phyto-antioxidants on survival and proliferation of ovarian cancer cells","volume":"110","author":"Raj","year":"2008","journal-title":"Gynecol Oncol"},{"key":"key20180108011816_b27-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.4161\/cbt.7.12.6939","article-title":"Silencing survivin results in synergy between methylseleninic acid and paclitaxel against skov3 ovarian cancer cells","volume":"7","author":"Azrak","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"key20180108011816_b28-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1158\/1078-0432.CCR-11-0233","article-title":"Silencing survivin splice variant 2B leads to antitumor activity in taxane - resistant ovarian cancer","volume":"17","author":"Vivas-Mejia","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180108011816_b29-mmr-07-02-0425","first-page":"361","article-title":"Comparative studies on the biological significance of the marker for proliferation Ki-67-antigen and PCNA in primary ovarian carcinoma","volume":"122","author":"Reitmaier","year":"2000","journal-title":"Zentralbl Gynakol"},{"key":"key20180108011816_b30-mmr-07-02-0425","first-page":"4823","article-title":"Interstitial collagenases as markers of tumor progression","volume":"6","author":"Brinckerhoff","year":"2000","journal-title":"Clin Cancer Res"},{"key":"key20180108011816_b31-mmr-07-02-0425","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jsgi.2003.11.003","article-title":"Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients","volume":"11","author":"Flick","year":"2004","journal-title":"J Soc Gynecol Investig"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mmr.2012.1216\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T11:50:17Z","timestamp":1714650617000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2012.1216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,3]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,12,3]]},"published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.3892\/mmr.2012.1216"],"URL":"https:\/\/doi.org\/10.3892\/mmr.2012.1216","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,3]]}}}